131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis. (May 2017)

• Record Type: Journal Article
• Authors: Rahimi, Behruz; Makis, William; Riauka, Terence A.; McEwan, Alexander J.B.; Morrish, Don
• Is Part Of: Clinical nuclear medicine. Volume 42:Number 5(2017)
• Publication Date: 2017-05
• Subjects: 131I-MIBG -- dosimetry -- hemodialysis -- neuroendocrine tumor -- renal insufficiency -- radioisotope therapy; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001601
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Systemic radioisotope therapy with 131 I-metaiodobenzylguanidine ( 131 I-MIBG) is an effective form of targeted therapy for neuroendocrine tumors. One of the absolute contraindications to administering 131 I-MIBG therapy listed in the 2008 European Association of Nuclear Medicine guidelines is renal insufficiency requiring dialysis, although this contraindication is not evidence based. We describe a 68-year-old woman with a metastatic small bowel neuroendocrine tumor who developed renal insufficiency requiring hemodialysis. Imaging and dosimetry with 131 I-MIBG were performed and showed that the radiation doses to the whole body and lungs were within safe limits. She was treated with 1820 MBq of 131 I-MIBG with no short-term adverse reactions.